Table 2.
Serum-neutralization titers of cohorts analyzed in this study.
| n | Median [IQR]a NT titer | ||||
|---|---|---|---|---|---|
| WT | Delta | Omicron BA.1 | Omicron BA.2 | ||
| Vaccinated group (3 doses, mRNA vaccine) | |||||
| 1-month samplesb | 15 | 640 (480-1120) | 320 (120-400) | 160 (80-280) | 160 (100-240) |
| 3-month samplesb | 15 | 160 (120-560) | 120 (70-280) | 40 (25-90) | 60 (30-100) |
| Convalescent and vaccinated group (WTc + 3 doses mRNA vaccine) | |||||
| 3-week samplesb | 9 | 640 (480-1280) | 480 (320-640) | 120 (80-320) | 240 (160-320) |
| WTc-infected group (primary infection) | |||||
| 3-week samplesb | 11 | 640 (400-640) | 160 (80-280) | 30 (25-40) | 40 (35-70) |
| 7-month samplesb | 11 | 160 (100-280) | 60 (40-100) | 20 (15-25) | 30 (20-35) |
| Omicron BA.1-infected group (primary infection) | |||||
| 1-month samplesb | 22 | ≤10 | ≤10 | 60 (22.5-105) | 17.5 (10-30) |
| Omicron BA.2-infected group (primary infection) | |||||
| 1-month samplesb | 21 | ≤10 | ≤10 | ≤10 | 20 (15-40) |
| Omicron-breakthrough infections | |||||
| 1-month samplesb | 43 | 960 (480-1920) | 480 (320-1120) | 320 (240-960) | 640 (160-960) |
a IQR, interquartile range; b median values after infection or vaccination; c WT, wildtype.